RxDoctor Payments Data

Jorge Flores, MD

Nephrology · Harlingen, TXNPI 1356380885

Payments from drug & device makers

$4,048in general payments, 2019–2025

Across 244 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$812
  • Vifor Pharma, Inc.$668
  • Akebia Therapeutics Inc$576
  • AstraZeneca$437
  • Bayer$406
  • Amgen$276
  • plus $874 from 15 others

What the payments were for

  • Food & beverage$3,99599%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,048 in reported general payments places this provider in the 65th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$321,465
Medicare patients
349
Services billed
2,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide144$328,967
AuryxiaFerric Citrate39$93,630
Sevelamer Carbonate146$50,004
LokelmaSodium Zirconium Cyclosilicate29$27,691
VeltassaPatiromer Calcium Sorbitex17$22,476
FarxigaDapagliflozin Propanediol37$20,374
Midodrine Hcl78$4,384
ProsolParenteral Amino Acid 20% No.121$4,061
Icosapent Ethyl11$2,303
Calcium Acetate22$1,689
Lactulose15$941
Minoxidil68$852
Hydralazine Hcl44$535
Nifedipine ErNifedipine29$479
Metoprolol Succinate45$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$812$328,967144 claims
Akebia Therapeutics IncAuryxia$576$93,63039 claims
AstraZenecaLokelma, Farxiga$437$48,06666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →